This site is intended for health professionals only

Lung cancer drug shows promise

teaser

Pemetrexed maintenance therapy for patients with non-small-cell lung cancer (NSCLC) improves overall and progression-free survival, according to a report in The Lancet.

The Eli Lilly drug was trialled as part of first-line treatment for patients who have received four cycles of platinum-based chemotherapy and not had disease progression.

Author Dr Chandra Belani concludes: “Pemetrexed maintenance therapy is well tolerated and offers significantly improved progression-free and overall survival, making it a new treatment option for patients with advanced non-squamous non-small-cell lung cancer who do not progress after initial induction therapy.”

The phase III study involved 663 patients with advanced NSCLC who had not progressed on four cycles of platinum-based chemotherapy.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

They were randomly assigned pemetrexed (500 mg/m2, day 1) plus best supportive care (441 patients) or placebo plus care (222) in 21-day cycles until disease progression.

Primary endpoint was progression-free survival and secondary endpoint overall survival. Standard first-line platinum-based chemotherapy historically provides modest improvements in overall survival.

Copyright Press Association 2009

Pemetrexed






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x